rubitecan has been researched along with Benign Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Dong, J; Gu, W; Lu, S; Peng, P; Xiong, Z; Xu, F; Yang, X | 1 |
| Gounder, M; Gu, Z; Kudelka, AP; Lee, SJ; Li, JM; Loyer, E; Rubin, EH; Thalasila, A; Verschraegen, CF | 1 |
| Feng, L; Gu, B; Han, X; Liu, J; Liu, M; Liu, Y; Lu, W; Xie, C; Zhan, C | 1 |
| Dadashzadeh, S; Derakhshandeh, K; Saghiri, R; Soheili, M | 1 |
| Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z | 1 |
| Cao, Z; Dejesus, A; Giovanella, B; Kozielski, A; Liu, X; Mendoza, J; Vardeman, D; Wang, Y; Zhan, CG | 1 |
| Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR | 1 |
| Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Agarwala, SS; Belani, CP; Egorin, MJ; Fakih, M; Friedland, DM; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Troetschel, M; Trump, DL; Vozniak, M; Wong, MM; Zamboni, WC | 1 |
| Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC | 1 |
| Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC | 1 |
| Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC | 1 |
| Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C | 1 |
| Ahmed, AE; Giovanella, BC; Jacob, S; Kozielski, AJ; Liehr, JG; Stehlin, JS | 1 |
| Edwards, CL; Ende, K; Freedman, RS; Giovanella, BC; Kavanagh, JJ; Kudelka, AP; Natelson, EA; Stehlin, JS; Verschraegen, CF | 1 |
| Gilbert, BE; Giovanella, BC; Knight, V; Koshkina, NV; Waldrep, JC | 1 |
| Abbruzzese, JL; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rubin, E; Siegler, D; Verschraegen, CF; Vincent, M | 1 |
11 trial(s) available for rubitecan and Benign Neoplasms
| Article | Year |
|---|---|
Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Cisplatin; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Remission Induction; Young Adult | 2008 |
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors | 2011 |
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2003 |
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome | 2004 |
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms | 2004 |
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2006 |
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide | 2006 |
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 1998 |
Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Neoplasms | 2000 |
8 other study(ies) available for rubitecan and Benign Neoplasms
| Article | Year |
|---|---|
Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cyclodextrins; Drug Carriers; Drug Delivery Systems; Drug Stability; Lactones; Liposomes; Mice; Mice, Inbred ICR; Neoplasms; Rats; Rats, Sprague-Dawley; Transferrin | 2015 |
9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Drug Evaluation, Preclinical; Folic Acid; HeLa Cells; Humans; Micelles; Neoplasms; Polymers | 2009 |
Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients.
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; In Vitro Techniques; Lactic Acid; Microscopy, Electron, Scanning; Nanomedicine; Nanoparticles; Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; X-Ray Diffraction | 2010 |
Anticancer activity of new haloalkyl camptothecin esters against human cancer cell lines and human tumor xenografts grown in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Esters; Humans; Mice; Mice, Nude; Models, Molecular; Neoplasms; Prodrugs; Transplantation, Heterologous | 2012 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptotheca; Camptothecin; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2004 |
Comparative disposition of the antineoplastic agent 9-nitrocampotothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Camptothecin; Infusions, Intravenous; Injections, Intramuscular; Isomerism; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Tissue Distribution; Tritium | 1997 |
Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Humans; Liposomes; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms; Particle Size | 1999 |